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I n November 2018, the Chinese researcherJiankui He claimed that he and his collea-gues had gene-edited human embryos,
resulting in the birth of twins with a modified
genome. His announcement was met with
near universal denunciation by leading scien-
tists, ethicists, and policymakers from all
over the world, including his home institu-
tion, the Southern University of Science and
Technology in Shenzhen. Notwithstanding
some nuances, they all condemned He’s
work on scientific and ethical grounds. A
total of 122 Chinese scientists issued an open
statement that “this presents a major blow to
the image and development of Chinese life
sciences on the global stage [. . .] and is extre-
mely unfair for the many honest and sincere
scholars working to adhere to moral practices
in the sciences” (http://3g.163.com/news/
article_cambrian/E1IBVFD20001899O.html).
The Chinese vice minister for science and
technology also weighed in: “The genetically
edited infant incident reported by media
blatantly violated China’s relevant laws and
regulations. It has also violated the ethical
bottom line that the academic community
adheres to. It is shocking and unacceptable”
(http://m.news.cctv.com/2018/11/29/ARTI
qnwNDtHx6ThPOqqWDmzI181129.shtml).
As a result, the Chinese government pledged
to launch a criminal investigation. In a
nutshell, a Chinese researcher who was
ensnared by the promise of ground-breaking
work made an inexcusable mistake. Across
the board, a central message was that He’s
work was a breach of trust—as for example
George Church argues [1].
Just individual misconduct?
But this is only one part of the picture.
While this scientific misconduct may still be
dealt with within the realm of science, there
are two more conceptual problems. The first
is the question of who should and could
decide on how a technology is used, for
what purpose, and with which societal
consent. While the birth of gene-edited chil-
dren may be a rogue action, it reveals that
there is insufficient oversight of the use of
CRISPR or other gene-editing technologies,
despite international efforts to find a
common position. There is no international
framework to monitor this research as
exists, for example, with the Biological
Weapons Convention to prevent the devel-
opment of biological weapons, or laws and
regulation about the release of genetically
modified organisms into the environment.
Such a framework is not only necessary in
order to define acceptable goals of research
and development, but, more fundamentally,
important in helping to establish a consen-
sus of public knowledge concerning scien-
tific evidence. Thus, the story of He and his
colleagues may be interpreted as an urgent
plea for finding a common ground on which
to discuss and weigh scientific facts and
evidence regarding manipulations of the
human germline.
The fact that He announced the birth of
CRISPR babies a few days before the
Second International Summit on Genome
Editing in Hong Kong is a reminder that
there have already been negotiations
within science as well as between science
and society. The starting point was the
publication of CRISPR/Cas experiments on
non-viable human embryos that explored
the prospect of human germline modifi-
cation [2]. This prompted a call for a
moratorium by scientists and the first
International Summit on Human Gene
Editing in Washington, D.C. in December
2015. This summit concluded with the need
to “reach a broad societal consensus about
the appropriateness of the proposed applica-
tion” of CRISPR [3]. The consensus—backed
by the Oviedo Convention as well as nearly
all scientific and political institutions—
seemed to be that gene-editing technologies
should be used for therapeutic applications,
but not for manipulating the human germ-
line in the context of reproduction.
Shifting perspectives
But this agreement has come under pres-
sure, in large part because of further
research that demonstrated the feasibility of
correcting mutations in human embryos [4]
as well as institutional statements that seem
to soften the stance against reproductive
germline editing [5]. Remarkably, the NAS
statement after an international summit on
gene editing in 2017 shows an important
shift as it changes from “not allowed as
long as the risks have not been clarified” to
“allowed if the risks can be assessed more
reliably”. This could be interpreted as
indicating that the US academies are no
longer focused on a partially fundamental,
partially risk-related rejection of germline
editing, but on a basic acceptance guided by
individual formal and material criteria:
from forbidden until criteria are met, to
permitted if criteria are met—even though
the criteria have not yet been agreed upon.
From this perspective, the ethical rationale
for editing the human genome did not
change with He’s experiment, but at least a
year before. Against this background, it
makes sense that He himself published five
ethical core principles just a few days
before he introduced Lulu and Nana to the
world.
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There is the additional issue of maintain-
ing a distinction between therapeutic and
non-therapeutic or enhancement applica-
tions. Case in point, the deletion of the CCR5
gene that He and his team carried out to
eliminate susceptibility to the HIV virus is in
a grey zone between therapy and enhance-
ment given that transmission of the HIV
virus from father to child is preventable by
other means, e.g. sperm washing. Leaving
aside the question of whether the edit will
be effective in the intended manner.
CRISPR and common ground
The second conceptual problem is the speci-
fic conditions under which to use emerging
biotechnologies such as CRISPR. In perhaps
their simplest definition, emerging biotech-
nologies are applications of expert knowl-
edge to achieve practical goals. But there are
at least two problems. Firstly, it implies that
the end goals of a technological invention
could be known in advance and that risks
can be addressed accordingly [6]. However,
CRISPR itself is a good example that risks
and difficulties, which were initially
assumed to be under control, can become
problematic. Second, a major lesson from
the past two decades of biotechnological
invention is that it is impossible to predict
not only if the aims of a project will be
achieved, but also if the potential applica-
tions will be societally recognized as valu-
able and the associated risks regarded as
acceptable.
......................................................
“While the birth of gene-edited
children may be a rogue
action, it reveals that there is
insufficient oversight of the use
of CRISPR or other gene-editing
technologies. . .”
......................................................
Dealing with this inherent unpredictabil-
ity requires research and regulatory institu-
tions that create stable and reliable
environments for research to proceed. In
this sense, institutions can be described as
trusted gatekeepers: not only by ensuring
that technologies are developed in an ethi-
cally and socially acceptable manner, but
also by helping to settle how much and
which scientific evidence is required to
proceed with applications. Within this line,
the crucial point surrounding He’s experi-
ment is not primarily whether He has
committed misconduct, but rather if the
institutional frameworks are still able—and
thereby trustworthy—to provide clear guid-
ance and norms. In order to develop scien-
tific regimes that are able to deal with the
inherent vagueness of gene-editing biotech-
nologies, we have to find a common ground
on the basis of which it would be possible to
define the aims and the conditions under
which these should be pursued.
......................................................
“. . . the ethical rationale for
editing the human genome did
not change with He’s
experiment, but at least
a year before.”
......................................................
The public consultations on gene editing
and their results are interesting and informa-
tive in this light [7,8]. Whenever there is a
promise of therapeutic benefit, attitudes tend
to be positive. Many interpretations of this
public attitude, including He’s, seem to stop
there, but another trend is equally impor-
tant. For example, the 2016 Pew Center
reports conclude that “when it comes to
using particular cutting-edge technologies to
potentially augment human abilities – such
as allowing parents to edit their baby’s
genes for a lifetime of much reduced disease,
people’s concern rises”. Moreover, “[s]ome
81% of adults say gene editing that would
give babies a much reduced risk of serious
diseases over their lifetime would cause
either a great deal of change for society
(46%) or some change (35%)” [9].
The larger picture
Too often when we speak of “ethics” in
biotechnology, we think about guidelines
and frameworks that regulate scientific prac-
tices. This is not wrong, but it risks missing
the forest for the trees. The purpose of ethi-
cal rules in social life is, in large part, to
mitigate vulnerability caused by, among
other things, disease and physical suffering.
Shared vulnerability can be a significant
motivation for solidarity and risk-sharing.
When scientific innovation creates the possi-
bility that some people will be able to use it
to shift their level of vulnerability vis-à-vis
the broader population, it raises concerns
about inequality that are clearly spelled out
in public consultations. It would be fool-
hardy and irresponsible to claim that the
deletion of the CCR5 gene undermines moral
and social equality, but it would be equally
remiss if we ignored the link between
advances in biotechnology and broader
concerns about inequality and the strength
of the social fabric. Indeed, a correlation
between certain types of biotech innovation
and fears of an erosion of risk-sharing or
rising inequality feeds simmering suspicions
about the model in which scientific research
and innovation are carried out, namely the
intertwining of academic research, industry,
and government. In other words, the
consensus on gene editing does not repre-
sent a common ground, but rather a linger-
ing sense of insecurity.
......................................................
“The purpose of ethical rules
in social life is, in large part, to
mitigate vulnerability caused
by, among other things,
disease and physical
suffering. . .”
......................................................
Subsequently, two questions need to be
asked: “Is it safe?” and “Who benefits?” The
conundrum is that trust in the response to
the first question is closely linked to the
response to the second. It is not just the ethi-
cal common ground that is unsettled, it is
the scientific evidence itself. This is because
the meaning of “safe” extends tacitly or
explicitly to the potential impact on the
social fabric, not just on individual patients.
In this regard, it is worthwhile to remember
that the stability of public knowledge—what
is accepted as fact about the world—is itself
politically conditioned by trust and security.
Thus, responses to public ethical consulta-
tion about gene-editing or other emerging
technologies cannot be neatly distinguished
from the ongoing political and economic
crisis that has gripped Europe and North
America since the 2008 financial crisis,
which expresses itself in governments and
populations that doubt “scientific facts”
when it comes to issues as diverse as climate
change and vaccinations. What the global
scientific and policy communities need to
understand is that what is accepted as scien-
tific fact, and the common-sense ethical
evaluation of what is acceptable and
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unacceptable application of biotechnology
cannot be separated from a broader context
of institutional and political trust, confi-
dence, and security.
......................................................
“. . . the meaning of “safe”
extends tacitly or explicitly to
the potential impact on the
social fabric, not just on
individual patients.”
......................................................
Openness and transparency are laudable
goals for science and the ethical debate
about the application of emerging technolo-
gies. But this openness does not exist in a
cultural bubble of settled scientific results
and evidence. If ethical and regulatory
debates about CRISPR or other technologies
are going to have broader societal traction
and impact, scientists, ethicists, and policy-
makers need to realize that “the facts” of
science are not settled, and that the idea of
settlement is closely tied up with a broader
social and political environment. Even in
the “post-truth” era, we cannot give in to a
distaste for the rough and tumble of democ-
racy as the philosopher and aristocrat Alexis
de Tocqueville expressed: “I accept the
intellectual rationale for democratic institu-
tions, but I am instinctively an aristocrat, in
the sense that I condemn and fear the
crowd. I dearly love liberty and respect for
rights, but not democracy”[10]. Scientific
research is too deeply tied up with society,
its impacts too wide, and the public
investments too great to ignore democratic
legitimation. Until the broader social and
political ground has stabilized, it is unlikely
that we will be able to find a common
ground for the ethical debate on gene-
editing or other emerging biotechnologies.
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